Innoviva Inc  

(Public, NASDAQ:INVA)   Watch this stock  
Find more results for INVA
16.74
-0.06 (-0.36%)
Feb 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 16.65 - 16.98
52 week 11.02 - 17.21
Open 16.75
Vol / Avg. 0.00/1.17M
Mkt cap 1.81B
P/E 14.95
Div/yield     -
EPS 1.12
Shares 107.87M
Beta 2.52
Inst. own 74%
Apr 25, 2018
Q1 2018 Innoviva Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Feb 8, 2018
Q4 2017 Innoviva Inc Earnings Call - Webcast
Feb 8, 2018
Q4 2017 Innoviva Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '17) 2017
Net profit margin 84.17% 61.81%
Operating margin 95.53% 84.53%
EBITD margin - 84.53%
Return on average assets 61.90% 35.98%
Return on average equity - -
Employees 12 -
CDP Score - -

Address

2000 Sierra Point Pkwy Ste 500
BRISBANE, CA 94005-1830
United States - Map
+1-650-2389600 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Innoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement and the Strategic Alliance Agreement with GSK, the Company is eligible to receive the annual royalties from GSK on sales of RELVAR/BREO ELLIPTA. For other products combined with a LABA from the LABA collaboration, such as ANORO ELLIPTA, royalties are upward tiering and range from 6.5% to 10%. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of a LABA (VI) and an inhaled corticosteroid (ICS), FF. ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA.

Officers and directors

William H. Waltrip Independent Chairman of the Board
Age: 78
Bio & Compensation  - Reuters
Eric D'Esparbes Interim Principal Executive Officer, Chief Financial Officer, Senior Vice President
Age: 49
Bio & Compensation  - Reuters
Theodore J. Witek Jr. Senior Vice President, Chief Scientific Officer
Age: 59
Bio & Compensation  - Reuters
George W. Bickerstaff III Independent Director
Age: 62
Bio & Compensation  - Reuters
Barbara G. Duncan Independent Director
Bio & Compensation  - Reuters
Catherine J. Friedman Independent Director
Age: 56
Bio & Compensation  - Reuters
Odysseas D. Kostas M.D. Independent Director
Age: 43
Bio & Compensation  - Reuters
Patrick G. LePore Independent Director
Age: 62
Bio & Compensation  - Reuters